Basel, 9 - 11 November 2021

Schedule

Create your personal agenda –check the favourite icon

Nov 909:05
Conference pass

Opening Remarks

Antibodies Opening Keynotes
Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre
Nov 909:10
Conference pass

Title TBA

Antibodies Opening Keynotes
Peter Senter, Vice President Of Chemistry, Seattle Genetics Inc
Nov 909:10
Conference pass

Title TBA

Biosimilars Opening Keynotes
Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency
Nov 909:35
Conference pass

Title TBA

Antibodies Opening Keynotes
Reserved for Fujifilm Diosynth Biotechnologies (CONFIRMED)
Nov 909:50
Conference pass

Keynote Panel Discussion: Topic TBA

Biosimilars Opening Keynotes
Martin Schiestl, Head of Regulatory Affairs, Sandoz (Novartis)
Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency
Nov 910:00
Conference pass

Keynote panel discussion: What does the future of Immunotherapy hold for Oncology and Infectious Diseases?

Immunotherapy Opening Keynotes
Nov 910:00
Conference pass

Sponsored keynote panel discussion: Next generation antibody therapeutics: discovery, development and beyond

Antibodies Opening Keynotes
Berkeley Lights (CONFIRMED)Panellists TBA
Nov 911:30
Conference pass

Adopting Biosimilars in an NHS Oncology setting 

Biosimilars Roundtables
Nov 911:30
Conference pass

Combination therapies with Cell therapies

Immunotherapy roundtables
Nov 911:30
Conference pass

Developability of multispecifics

Antibodies Roundtables
Nov 911:30
Conference pass

Gene-engineering and combinatorial therapy approaches for tacking solid tumors

Immunotherapy roundtables
Nov 911:30
Conference pass

Immune cells as biomarkers of response or resistance to antibody immunotherapies

Immunotherapy roundtables
Nov 911:30
Conference pass

Immunogenicity risk assessment

Antibodies Roundtables
Nov 911:30
Conference pass

Selection of immunomodulatory payloads to OV therapeutics

Immunotherapy roundtables
Nov 911:30
Conference pass

Table 1 - Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, and Fc fusion proteins

Antibodies Roundtables
Nov 911:30
Conference pass

Targeting innate immunity in solid cancer therapy

Immunotherapy roundtables
Nov 911:30
Conference pass

Title TBA

Immunotherapy roundtables
Nov 911:30
Conference pass

Title TBA

Immunotherapy roundtables
Nov 911:30
Conference pass

Title TBA

Immunotherapy roundtables
Nov 911:30
Conference pass

Title TBA

Biosimilars Roundtables
Nov 911:30
Conference pass

Title TBA

Biosimilars Roundtables
Nov 911:30
Conference pass

Title TBA

Biosimilars Roundtables
Nov 911:30
Conference pass

Title TBA

Biosimilars Roundtables
Nov 911:30
Conference pass

Title TBA

Biosimilars Roundtables
Nov 914:00
Conference pass

Aggregates formation after mixing biopharmaceuticals with human plasma and blood: comparison of originator and biosimilar products

Biosimilars Manufacturing, Analysis, Research and Development
Tudor Arvinte, President And Chief Executive Officer, Therapeomic Inc
Nov 914:00
Conference pass

Bispecific gamma-delta T cell engagers

Bispecifics & Multispecifics
  • Next generation T cell engager platform
  • Mechanism of action of LAVA’s CD1d gamma-delta bsTCE
  • Progress towards the clinic
Paul Parren, EVP, Lava Therapeutics
Nov 914:00
Conference pass

Co-stimulatory single-chain TNFSF ligands as building blocks for bispecific fusion proteins

Innate & Adaptive Checkpoint Inhibition
  • The engineering concept of scTNFSFligands in different bispecific formats will be presented
  • Immune-stimulatory scTNFSF-ligands can be combined with any antibody of interest in a bispecific drug compound
  • Examples demonstrating the biological activity of scCD40L or sc4-1BBL in combination with anti-PD-L1 will be shown
Nov 914:00
Conference pass

Novel tumor targets and TCRs for Adoptive Cell Therapies and TCR Bispecifics for the treatment of solid tumors

Manufacturing, Commercialisation & Market Access
  • Immaticsis a clinical-stage company focused on the development of TCR-based immunotherapies against novel targets for solid tumors
  • TCRs against these tumor targets are used in various Adoptive Cell Therapy and TCR Bispecific programs
  • The talk will provide an update onImmaticsclinical and preclinical programs for both therapeutic modalities
Ali Mohamed, Vice President, CMC, Immatics Inc
Nov 914:00
Conference pass

Phase I/II clinical data using LOAd703 in pancreatic cancer

Oncolytic Viruses
  • LOAd703 is a virus expressing CD40L and 4-1BBL in the tumor microenvironment to stimulate anti-tumor immunity
  • Results demonstrating immune changes in the tumor microenvironment in different solid tumors post treatment will be presented
  • Results from a Phase I/II clinical trial in pancreatic cancer will be presented
Angelica Loskog, Chief Executive Officer, Lokon Pharma
Nov 914:00
Conference pass

The challenges of global commercialisation for a biosimilars player

Biosimilars Commercialisation and Market Access
Jenny Hao, Managing Director, Access Now
Nov 914:00
Conference pass

Title TBA

Protein Engineering
David O'Connell, Assistant Professor, School Of Biomolecular And Biomedical Science, University College Dublin
Nov 914:00
Conference pass

Title TBA

Infectious Disesaes
Andreas Hougaard Laustsen, Postdoctoral, Technical University of Denmark
Nov 914:00
Conference pass

Title TBA

Manufacturing & Bioprocessing
Martin Bertschinger, Deputy Cell Sciences Director, Ichnos Sciences
Nov 914:00
Conference pass

T-SIGn tumor reengineering: reprogramming the tumor microenvironment to drive anti-tumor immunity

Cell & Gene Therapy
Brian Champion, CSO, PsiOxus Therapeutics Ltd
Nov 914:20
Conference pass

Accelerating bioprocess workflows with microfluidic, immunoassay-based parallel impurity analysis

Manufacturing & Bioprocessing
Impurities in biologics cell culture manufacturing and bioprocess purification steps such as host cell proteins (HCPs), culture-related impurities, and process-related impurities can potentially reduce therapeutic efficacy and cause immunogenic reactions in patients. Minimizing the level of impurities during bioprocess development is therefore a critical regulatory requirement. Gyrolab® Systems have become established analytical tools for performing immunoassay-based bioprocess impurity bioanalysis in a regulated environment. The unique microfluidic, flow-through assay format dramatically reduces reagent and sample volumes and eliminates long incubation times common in ELISAs routinely used for impurity analysis. Here we present data on the quantitation of a variety of impurities found in bioprocess samples including Chinese Hamster Ovary (CHO) cell line HCPs and insulin cell culture impurities using Gyrolab assay kits and protocols. Results demonstrate dynamic range, precision, dilutional linearity, and spike data that fulfills key regulatory bioanalytic method requirements and is comparable or superior to ELISA methods.
Nov 914:20
Conference pass

Biosimilars in Denmark. High Uptake and Low Prices. What’s the Story?

Biosimilars Commercialisation and Market Access
  • Belief in Science
  • Health Authorities
  • Procurements, tenders and pricing
  • Stakeholder participation
  • Information to patients
  • A miracle-or just common sense and cooperation?
Peter Jorgensen, Director of the Industrial Ass, Danish Generic and Biosimilar Medicines Industry Association (IGL)
Nov 914:20
Conference pass

Expanding the therapeutic window of CD3-engaging DART® molecules via CDR masking and affinity modulation of the CD3 arm

Bispecifics & Multispecifics
CD3-engaging bispecifics mediate potent redirected T-cell killing in vitro and anti-tumor activity in vivo. However, their dosing is often limited by systemic cytokine release or off-tumor activity. Examples will be shown how modulating the affinity of CD3 engagement and masking of CDRs outside of tumor tissue might improve the activity and safety profile of next-generation CD3-engaging DART molecules.
Gundo Diedrich, Senior Director, MacroGenics
Nov 914:20
Conference pass

Identification of Novel pHLA Targets to Enable Targeting of Solid Tumors with High Potency Compounds

Cell & Gene Therapy
  • Advantages of intracellular targets (pHLAs) versus conventional cell surface antigens
  • Start with the end in mind: TCRs and targets from patients responding to CPI treatment
  • Strategies to find the most prevalent and immunogenic targets in CPI responders
  • Selection of pHLA targets with highest tumor vs normal tissue rations to avoid off-tumor target toxicities of ADCs, Bispecifics, TCR-T and CAR-T cell therapies
Hanspeter Gerber, CSO, 3T Biosciences
Nov 914:20
Conference pass

Title TBA

Infectious Disesaes
Mart Ustav, CSO, Icosagen Cell Factory OU
Mart Ustav, CSO, Icosagen Cell Factory OU
Nov 914:20
Conference pass

Title TBA

Oncolytic Viruses
Jutta Petschenka, Principal Scientist, Boehringer Ingelheim
Nov 914:20
Conference pass

Title TBA

Biosimilars Manufacturing, Analysis, Research and Development
Sridevi Khambhampaty, Vice President Biosimilar Product Development And Regulatory Affairs, Intas Pharmaceuticals Ltd
Nov 914:20
Conference pass

Twist Biopharma: Writing the Future of Biologics to Discover and Optimize Single Domain Antibodies

Protein Engineering
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions including a panel of highly diverse synthetic naïve single domain antibody phage display libraries. In this presentation, Aaron will give an overview of these libraries and present several case studies.
Nov 914:40
Conference pass

Antibody engineering to fight infectious diseases and cancer

Protein Engineering
  • Human antibodies to infections diseases, e.g. neutralizing SARS-CoV-2
  • Ultra fast development of a therapeutic antibody from the scratch to clinic
  • Antibody engineering tricks to improve efficiency and safety
Stefan Duebel, Director, Technical University of Braunschweig
Nov 914:40
Conference pass

Development of glyco-humanized neutralizing polyclonal antibodies against SARS-CoV-2

Infectious Disesaes
  • Glyco-humanization of heterologous polyclonal antibodies allow safe administration in humans.
  • XAV-19 is a polyclonal antibody against SARS-CoV-2 showing potent neutralizing activity against Wuhan, UK and SA strains.
  • POLYCOR and EUROXAV clinical trials are ongoing to evaluate safety and efficacy of XAV-19 in moderate to severe hospitalized and outpatients presenting with COVID-19.
Nov 914:40
Conference pass

Multidimensional personalized response assessment to microglia modulators in glioblastoma bioreactors

Innate & Adaptive Checkpoint Inhibition
  • Using CODEX technology, we provide an indepth characterization of the umor microenvironment in different regions of the same tumor
  • To evaluate the effect of TAM-modulating therapies in combination with T-cell checkpoint inhibitor approaches, we generated 3D GBMbioreactor cultures from patient-derived samples
  • We report patient-tailored, tumor region specific response assessment to microglia modulators and checkpoint inhibitors using multidimensional fluorescent microscopy techniques (CODEX), and multiplexed cytokine release
Nov 914:40
Conference pass

Title TBA

Manufacturing & Bioprocessing
Senior Representative, Bio-Techne: Digital Solutions
Nov 915:00
Conference pass

Addressing unmet patient needs in immune-inflammatory diseases through monoclonal / bispecific antibodies

Bispecifics & Multispecifics
Almirall is a mid-size pharm dedicated to medical dermatology. Primary focus is on providing treatment options to patients suffering from severe skin diseases and help them to get closer to a healthy life. This presentation analyses current therapeutic antibody concepts targeting potential immune-mediated inflammatory diseases drivers. Some of those concepts validated in the clinic others showed rather low efficacy or failed. Thus, high unmet medical needs remain, in particular for more heterogeneous diseases. We share how we think about understanding and tackle the remaining unmet medical needs with monoclonals and bispecific antibodies.
Thomas Huber, Research director, Almirall
Nov 915:00
Conference pass

Efficient NK cell redirection by targeting natural cytotoxicity receptor NKp30

Protein Engineering
  • Activating NK cell receptors represent promising targeting structures to elicit potent anti-tumor immune responses
  • Novel NK cell engagers were constructed by bridging EGFR on tumor cells with NKp30 on NK cells
  • Different formats for NK cell redirection will be discussed
Stefan Zielonka, Associate Director, Protein Engineering And Antibody Technologies, Merck KGaA
Nov 915:00
Conference pass

Human B cell responses to emerging infections

Infectious Disesaes
  • New single-cell technologies that enable rapid discovery
  • Rapid functional testing facilitates early antibody lead selection
  • New capabilities to discover broadly reactive antibodies
Nov 915:00
Conference pass

Preclinical development of NI-1801, a CD47xMesothelin bispecific antibody to treat solid tumors

Innate & Adaptive Checkpoint Inhibition
  • Tumor specific CD47 targeting with a bispecific antibody strategy
  • Preclinical efficacy of the NI-1801 in comparison with an anti-mesothelin mAb
  • Preclinical safety of NI-1801
Nov 915:00
Conference pass

The challenges of global commercialisation for a biosimilars player

Biosimilars Commercialisation and Market Access
  • The commercialization of biosimilars in a harmonized regulatory global frame
  • From regional to global – How to become a global biosimilar player in a fast-changing commercialization arena
  • The experience in Latin America: How to foster the uptake in a growing emerging market – Identifying the key stakeholders for a successful adoption
Eduardo Cioppi, Global Market Access & Public Affairs Director, mAbxience Research S.L.
Nov 915:00
Conference pass

Unique cancer and anti-infective immunotherapy platforms

Oncolytic Viruses
  • ValoTx has developed novel, uniquely flexible and broadly applicable immunotherapy platforms targeting multiple disease specific antigens
  • PeptiCRAdis an oncolytic adenovirus based cancer immunotherapy platform entering clinical testing in 2021
  • PeptiVAXis a vaccine platform for infectious disease - preclinical proof of principle data has been generated
Nov 915:20
Conference pass

Blood-Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies to TfR1

Protein Engineering
  • Development of BBB shuttles using single domain VNAR antibodies
  • Efficient delivery of biologic payloads to the brain – PoC studies in mice
  • Successful translation to non-human primates
Pawel Stocki, Reseach Director, Ossianix, Inc.
Nov 915:20
Conference pass

Cysteine in cell culture media induces acidic IgG1 species by disrupting the disulfide bond network

Manufacturing & Bioprocessing
  • In this study, the promoting effect of cysteine on monoclonal antibody (mAb) acidic charge variants is demonstrated in in vitro and in cell culture based experiments.
  • The presence of cysteine was linked to ruptured and modified disulfide bonds, leading to enhanced levels of acidic species.
  • The data highlights cysteine in cell culture media as key player for manipulating mAb charge during the fermentation process.
Nov 915:20
Conference pass

Enabling Market Access In the US

Biosimilars Commercialisation and Market Access
Meaghan Smith, Executive Director, The Biosimilars Forum
Nov 915:20
Conference pass

Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific

Innate & Adaptive Checkpoint Inhibition
  • PRS-343 is the first bispecific to enter the clinic which is engineered to specifically activate 4- 1BB in the tumor microenvironment
  • PRS-343 demonstrated durable anti-tumor activity in heavily pre-treated patient populationacross multiple tumor types, including those usually not responsive to immune therapy; novel and non-redundant MoA among HER2- targeting therapies and checkpoint inhibition
Nov 915:20
Conference pass

State-of-the-art analytical methods for originator and biosimilar characterization

Biosimilars Manufacturing, Analysis, Research and Development
  • Critical Quality Attributes ranking
  • Multi-dimensional analytical workflows
  • Multi-levelmAbsand Fc-fusion proteins characterization
Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre
Nov 915:20
Conference pass

Strategies to enhance systemic antitumor immunity elicited by oncolytic viruses

Oncolytic Viruses
Christophe Queva, Chief Scientific Officer, Oncorus
Nov 915:20
Conference pass

The Rise of the Next Generation of T-cell Engagers

Cell & Gene Therapy
  • The holistic approach to designing multispecifics
  • Designing T-cell engager platforms for better therapeutic windows
  • Targeting solid tumors with TCEs
Nov 915:20
Conference pass

Three arms are better than two: avidity driven selectivity for T-cell bispecifics

Bispecifics & Multispecifics
  • Identified a pair of antigens coexpressed on breast cancer cells but not on normal tissue
  • Demonstrated a high affinity T-cell bispecifics versus one of the antigens drives both tumor regression and on-target toxicity
  • Showed trispecific Abs with optimized affinities and other attributes are able to reduce on-target toxicity while maintaining efficacy
Nicholas Agard, Scientist, Genentech
Nov 915:20
Conference pass

Title TBA

Infectious Disesaes
Marit van Gils, Associate Professor, Amsterdam UMC
Nov 916:30
Conference pass

A bispecific antibody agonist of the IL-2 heterodimeric receptor promotes in vivo expansion of CD8 and NK cells

Bispecifics & Multispecifics
  • Development and activity of bispecific antibodies that simultaneously bind and activate IL-2Rβγ
  • Bispecific anti-IL-2Rβγ antibodies avoid IL-2Rα and toxicities associated with the trimeric receptor
  • IL-2Rβγ agonist antibodies expand T and NK effector cells both in vitro and in vivo and avoid preferential expansion of Tregs
Nov 916:30
Conference pass

Immunogenicity and Immunotoxicity of biologics

Immunogenicity
  • Adverse effects of biologics mediated by the immune system
  • How immunogenicity affects the outcome of the therapeutic response
  • Mechanisms of biologics immunogenicity
Marc Pallardy, Professor and head of the Department of Toxicology, Universite Paris Sud
Nov 916:30
Conference pass

Rapid discovery and development of antibodies for Covid-19

Infectious Disesaes
Blaine Stine, Director, Global Biologics Discovery, Abbvie
Nov 916:30
Conference pass

The CD47-SIRPα innate immune checkpoint in cancer

Innate & Adaptive Checkpoint Inhibition
  • Innate immune cells as cytotoxic effector cells in cancer
  • Enhancing effector function by targeting CD47-SIRPα
  • Clinical progress
Nov 916:30
Conference pass

Title TBA

Protein Engineering
John Lofblom, Professor in Combinatorial Protein Engineering, K.T.H. Royal Institute of Technology
Nov 916:30
Conference pass

Value Based Agreements and Biosimilars - innovative contracting and new payer perspectives with biosimilars

Biosimilars Commercialisation and Market Access
Omar Ali, Visiting Lecturer, University of Portsmouth
Nov 916:30
Conference pass

Viral Backbone and the design of Oncolytic Viral therapies for intravenous delivery

Oncolytic Viruses
Nov 916:50
Conference pass

IgG-like bispecific antibody design and discovery for multiple immuno-oncology target pairs

Bispecifics & Multispecifics
  • Design of a developable IgG-like bispecific antibody format
  • Simultaneous multiple target antibody discovery
  • mAb and bsAb characterisation and early development
Christopher Plummer, Antibody Selections Team Leader, GSK
Nov 916:50
Conference pass

Non-clinical immunogenicity assessment : an update of the T cell response specific for therapeutic antibodies

Immunogenicity
  • Methologies and their outcomes
  • Location and function of T cell epitopes
  • Improving affinity while reducing T cell epitope content
Bernard Malliere, Head of laboratory, CEA
Nov 916:50
Conference pass

The impact of immune environment on checkpoint blockade

Innate & Adaptive Checkpoint Inhibition
  • Antibody drug classes have different Fc requirements for optimal activity
  • The local immune environment can impact immune checkpoint blocker efficacy
  • Can a suboptimal environment be overcome to enhance responses?
Nov 916:50
Conference pass

Title TBA

Protein Engineering
Reserved for AbCellera
Nov 916:50
Conference pass

Unleashing the Titans: the GEN-011 Neoantigen-targeted Peripheral T cell Therapy for Solid Tumors

Cell & Gene Therapy
  • Adoptive T cell therapies have resulted in unprecedented efficacy against solid tumors
  • Prioritizing neoantigens with the ATLASTM bioassay identifies the right targets and avoids pro-tumor InhibigensTM
  • The GEN-011 neoantigentargeted peripheral T cells(NPTs) have broad specificity and are nonexhausted, polyfunctional, cytolytic cells
  • The TITAN-1 clinical trial is ongoing (NCT04596033)
Nov 917:10
Conference pass

At the interface with Contract Manufacturers: the key for effective relationship management

Manufacturing, Commercialisation & Market Access
  • Contract manufacturing of products at all stages and of all kinds is a trend across the pharmaceutical industry
  • While it offers clear advantages in terms of cost and resource allocation, at times maintaining a productive relationship with the CMO is challenging
  • This presentation will cover real life examples and learnings of years of interactions with CMOs, while transferring a process or overseeing regular commercial activities
Nov 917:10
Conference pass

Epitope profiling of coronavirus-binding antibodies using computational structural modelling

Infectious Disesaes
  • Here, we describe a novel computational method for epitope profiling based on structural modelling and clustering. We apply it to a large database of antibodies all shown experimentally to bind coronaviruses.
  • Our approach functionally links antibodies based on similar predicted structure, transcending genetic lineage, species origin and coronavirus specificity. The resulting structure-function relationships yield new opportunities to identify repertoire functional convergence hitherto missed by sequence-only analysis.
  • These results also demonstrate the value of large virus family-specific antibody databases both for pandemic preparedness and for understanding the full diversity of antibodies that can engage a given antigen binding site.
Matthew Raybould, Postdoctoral Researcher, University of Oxford
Nov 917:10
Conference pass

Notch-dependent Myeloid Cell Regulation

Innate & Adaptive Checkpoint Inhibition
  • Notch-signalling is a highly conserved pathway often involved in cell-fate decisions
  • Notch signalling plays a role in development and homeostasis of immune cells
  • Targeting the Notch pathway could be employed to affect myeloid cell composition
Nov 917:10
Conference pass

Title TBA

Protein Engineering
Colette Johnston, Senior Director, Early Discovery, Crescendo Biologics Ltd
Nov 917:30
Conference pass

A Practical Approach to Mitigating Immunogenicity Concerns in Novel Biotherapeutics

Immunogenicity
  • Overview of current methodologies
  • Use cases for in silico or in vitro methods
  • Effectively implementing a mitigation strategy
Samuel Pine, Head of Bioanalysis and Immunogenicity, Ablynx, a Sanofi company
Nov 917:30
Conference pass

Development of a T-cell centred oncolytic virus against solid tumors

Oncolytic Viruses
  • TILT-123 is an oncolytic adenovirus developed after a number or optimization rounds to achieve best inclass Pharmacokinetic and Pharmacodynamic properties.
  • Conclusions from human data were taken back to the lab for validation and showed the promise of use of TILT-123 to enable immune checkpoint inhibitors, CAR T-cell therapy and ACT-TIL therapy.
  • Clinical development is ongoing where the use of TILT-123 with different T-cell therapies is being studied for different solidtumorindications.
Nov 917:30
Conference pass

iNKT-based cell therapy for treatment of tumors

Cell & Gene Therapy
  • iNKT cells, a powerful vehicle for cell therapy
  • Enhancement of iNKT killing using CARs
  • CARDIS: a novel platform for discovery of specific, highly functional CARs
Nov 917:30
Conference pass

Multispecific MATCH antibodies – novel therapeutics with tumor targeted immunomodulatory functions and beneficial safety profile

Bispecifics & Multispecifics
  • Therapeutic approaches based on Numab’s MATCHTM platform aim at multispecific designs with superior efficacy and favorable safety.
  • NM21-1480 is a trispecific scMATCH-3 currently in phase 1 clinical testing that potently stimulates anti-cancer immune responses by tumor-localized activation of the immune stimulatory receptor 4-1BB and concomitant blockade of the immune suppressive PD-L1 pathway.
  • Relevance of molecular formats, 4-1BB epitopes and relative affinities to each target protein to exploit the full synergistic potential of dual pathway modulation and at the same time to avoid systemic activity/toxicity.
Tea Gunde, Chief Research Officer, Numab Therapeutics AG
Nov 917:30
Conference pass

Title TBA

Infectious Disesaes
Thomas Schirrmann, CEO & Founder, CORAT Therapeutics
Nov 917:30
Conference pass

Title TBA

Protein Engineering
Madan Paidhungat, Director, Protein Engineering, Cytom X Therapeutics
Nov 917:30
Conference pass

Title TBA

Manufacturing, Commercialisation & Market Access
Nov 917:30
Conference pass

Title TBA

Biosimilars Manufacturing, Analysis, Research and Development
Nov 917:50
Conference pass

Human monoclonal antibodies as therapeutics against SARS-COV-2 and related viruses

Infectious Disesaes
  • Rapid identification of human antibodies by phage display
  • High affinity/avidity to SARS-CoV-2 S glycoprotein and mutants found in patients (Li W et al PNAS, Cell; Sun Z et al mAbs, 2020; Zhu X et al PLOS Biology, Sun Z et al bioRxiv, 2021) as well as to bat coronavirus S receptor binding domains.
  • Potent and specific neutralization of SARS-CoV-2 in hACE2 expressing transgenic mice and hamsters as well as mouse ACE2 adapted SARS-CoV-2 in wild type BALB/c mice at doses as low as 2 mg/kg.
Nov 917:50
Conference pass

Targeting of tumor-specific peptide antigens with bispecific T Cell-Engaging Receptor (TCER®) molecules

Bispecifics & Multispecifics
  • Update on Immatics’ T cell-engaging receptors (TCER®) pipeline
  • Development and preclinical validation of bispecific molecules equipped with soluble, high-affinity T cell receptors
Nov 917:50
Conference pass

The role of biosimilars in the Polish reimbursement system

Biosimilars Commercialisation and Market Access
  • P&R decision making in Poland
  • Biosimilar status and importance
  • Examples, benefits and challenges
Marcin Czech, Professor, Institute Of Mother And Child
Nov 917:50
Conference pass

Title TBA

Biosimilars Manufacturing, Analysis, Research and Development
Andreu Soldevila, Chief Executive Officer, Syna Therapeutics

Create your personal agenda –check the favourite icon

Nov 1009:00
Conference pass

Opening Remarks

Antibodies & Immunotherapy Keynotes
Nov 1009:05
Conference pass

Novel approaches for antibody cancer immunotherapy

Antibodies & Immunotherapy Keynotes
Dr Christian Klein, Dept Head, Roche Pharmaceutical Research and Early Development
Nov 1009:30
Conference pass

Accelerating Novel Immunotherapeutic Modality Discovery through Digitalization

Antibodies & Immunotherapy Keynotes
The advent of novel immunotherapeutic modalities, including next-generation antibodies, cell & gene therapies and RNAs, has resulted in massive amounts of complex R&D data needing to be systematically structured and interpreted. We present case studies showing how biopharma and biotech organizations digitalize and automate their bi- and multi-specific antibodies, AAV, CAR-T, and TCR-T workflows and how they leverage having full traceability and data integrity for data sciences and ML approaches.
Nov 1009:55
Conference pass

PD-1 antibodies either as precision medicine informed monotherapy or combinations are transforming cancer care

Antibodies & Immunotherapy Keynotes
Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
Nov 1009:55
Conference pass

Regulatory lessons learnt from the past 15 years and what can regulatory guidelines do to improve access going forward?

Biosimilars Day 2 Opening Keynotes
2021 marks 15 years since the European Union approved the first biosimilar. In this session panellists will discuss the regulators’ role in ensuring swift and efficient access to Biosimilars and factors that could improve future access.
Nov 1011:30
Conference pass

Clinical Efficacy Testing of Biosimilars is not Necessary--an FDA perspective?

Biosimilars Sustainability
  • Is it possible to design a meaningful clinical efficacy testing for biosimilars?
  • Does the history of clinical efficacy testing supportbiosimilarityclaims beyond what is already established?
  • Is indication extrapolation possible if clinical efficacy is required for approval of biosimilars?
Sarfaraz Niazi, Professor, University of Illinois
Nov 1011:30
Conference pass

Oxidative post translational modification (oxPTM) and autoimmune diseases

Non-Oncology Immunotherapy
  • Humoral response tooxPTMin rheumatic disease
  • Humoral response tooxPTMin autoimmune diabetes
  • T cell response tooxPTMneoepitopes
Ahuva Nissim, Professor, William Harvey Research Institute
Nov 1011:30
Conference pass

Preclinical models to evaluate potent off-the-shelf combination treatment for T cell redirection against tumors

Combination Therapies
  • Introduction into the preclinical model platform for CIT evaluation developed at the Roche Innovation Center Zurich (part of Roche pharma Research and Early Development, pRED)
  • Key features of the T cells engagers and targeted immunocostimulators platforms developed in Roche pRED Oncology Discovery
  • Preclinical in vivo profiling of immunotherapy combination to optimally stimulate anti-tumor T cell responses
Nov 1011:30
Conference pass

Targeting Tumor Neo-epitopes with Therapeutic Monoclonal Antibodies

Neoantigens & Therapeutic Vaccines
  • Platform using therapeutic cancer vaccine used to produce immunogenic monoclonal antibodies
  • Development and characterization of monoclonal antibodies
  • Clinical Trials utilizing Neo-epitope targeted therapy
Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc
Nov 1011:30
Conference pass

Title TBA

Biosimilars Regulation and Policy
Martin Schiestl, Head of Regulatory Affairs, Sandoz (Novartis)
Nov 1011:40
Conference pass

State of the art characterization of antibody based products

CMC & Developability
  • LC and LC-MS improvements (ultra-short columns, additives) and CE-MS
  • Native MS, Ion Mobility, Collision-Induced Unfolding, PASEF
  • mAbs, biosimilars, Fc-fusion proteins and peptides, BsAbs and ADCs
Alain Beck, Senior Director, Centre d'Immunologie Pierre Fabre
Nov 1011:40
Conference pass

Title TBA

Armed Antibodies
Thomas Pillow, Senior Scientist, Genentech
Nov 1011:40
Conference pass

Title TBA

Protein Engineering
Armin Sepp, Scientific Leader And Gsk Associate Fellow, GlaxSmithKline
Nov 1011:40
Conference pass

Title TBA

Bispecifics & Multispecifics
John Delaney, Director, Research Technologies And Collaborations, Amgen Inc
Nov 1011:50
Conference pass

Active immunization against a-synuclein for the prevention and treatment of Parkinson’s disease and other synucleopathies

Non-Oncology Immunotherapy
  • Vaxxinity’smodular vaccine platform
  • Preclinical evidence supporting UB-312 as a candidate vaccine
  • Safety and immunogenicity of UB-312 in healthy individuals
Nov 1011:50
Conference pass

Cytokine tethering safely endows adoptively transferred T cells with superior anti-tumor efficacy

Cell & Gene Therapy
  • Adoptively transferred T cells have shown remarkable anti-tumor efficacy in blood cancers, but theirefficacy against solid tumors has been limited
  • We will hear how tethering cytokines to Repertoire Immune Medicines’s tumor antigen targeted T cells enhances their efficacy against solid tumors without causing significant toxicities
  • We will also discuss how decoding of matched tumor antigen epitopes and T cell clonotypes in a patient's HLA context combined with deep immunoprofiling can instruct improved therapeutics and more efficient clinical trial designs
Nov 1011:50
Conference pass

Late-stage clinical development of a personalized vaccine platform technology for cancer and COVID-19

Neoantigens & Therapeutic Vaccines
  • A pan antigenic approach, protecting against mutation-associated loss of function
  • A personalized medicine, which minimizes adverse events and maximizes efficacy
  • A scalable and readily available platform
Nov 1011:50
Conference pass

WHO International Standards for Biosimilars: Tools for harmonizing bioactivity and clinical use

Biosimilars Sustainability
  • Concept of International Standards
  • Recent developments in bioactivity standards for monoclonal antibodies
  • Role of international standards in clinical monitoring
  • Future pipeline
Meenu Wadhwa, Section Leader For Cyotkines And Growth Factors Section, NIBSC
Nov 1012:00
Conference pass

Novel approaches to native antibody modification by exploiting native disulfides

Bispecifics & Multispecifics
  • A novel method to analyze binding kinetics (association/dissociation rates) on cells
  • Trapping of cells in flow channel of commercially available biosensor using meshlike cages
  • Single-cell analysis in an automated workflow
Nov 1012:00
Conference pass

Novel approaches to native antibody modification by exploiting native disulfides

Armed Antibodies
  • Functional disulfide re-bridging
  • Cysteine-to-lysine transfer reagents
  • Reversible covalent conjugation
  • Use of chemical linkers to form bi- and tri-specifics.
Vijay Chudasama, Reader, UCL
Nov 1012:00
Conference pass

Title TBA

Protein Engineering
Pascal Egloff, Platform Leader, University of Zurich
Nov 1012:00
Conference pass

Title TBA

CMC & Developability
Reserved for Abzena
Nov 1012:10
Conference pass

INO-4800 – A DNA based vaccine against COVID-19 Efficacy in an

Non-Oncology Immunotherapy
  • Efficacy in animal challenge models
  • Phase 1 immunogenicity and safety profile
  • Thermo stability of DNA vaccines
  • Enhanced delivery through electroporation
Nov 1012:10
Conference pass

Novel approaches to TNF superfamily antagonism

Combination Therapies
  • New antibody designs for TNF Superfamilies
  • TNFR2 for cancer
  • CD40 for autoimmunity
Nov 1012:10
Conference pass

Title TBA

Biosimilars Regulation and Policy
Richard Frank, Health Economics Professor, Harvard University
Nov 1012:10
Conference pass

Uptake of Biosimilars by Oncologists

Biosimilars Sustainability
Hanmant Barkate, Senior Vice President, Global Medical Affairs, Glenmark Pharmaceuticals SA
Nov 1012:20
Conference pass

Accelerating Antibody Engineering with Modern Informatics

Protein Engineering
  • Antibody engineering is now more streamlined than ever, but several factors contribute to its complexity such as persistent concerns around immunogenicity, increasing diversity of antibody formats, and the need for comprehensive characterization.
  • There is a need for a modern informatics solution that can adapt to the complex science and provide meaningful insights to make critical program-level decisions.
  • This presentation will highlight some of the critical considerations in evaluating an informatics solution to accelerate antibody engineering.
Nov 1012:20
Conference pass

intein-mediated high throughput screening of bispecific antibodies

Bispecifics & Multispecifics
  • Split inteins enable reconstitution of bispecific antibodies on the protein level
  • Comparability to genetically fused bispecifics and automation are discussed
  • Broad combinatorial screening for identification of optimal bispecific antibodies
Nov 1012:20
Conference pass

Title TBA

CMC & Developability
Horst Bierau, Senior Scientific Advisor - Head CMC Science & Intelligence, Merck Serono
Nov 1012:30
Conference pass

Boosting immuntherapy efficacy with epidrugs in oncology

Combination Therapies
  • Immunotherapy has been a breakthrough in oncology buthas efficacy in small proportion of patients
  • Epigenomic modulation has been shown to impact immunotherapy efficacy
  • Ongoing clinical trials evaluate the combination of epidrugs with immunotherapy
Nov 1012:30
Conference pass

Fostering sustainable access to biosimilars

Biosimilars Sustainability
  • How to support biologic competition and reinvestment in healthcare?
  • What can we learn from front runners: Key differentiation & success factors in biosimilar policy?
  • Emergingchallenges :Healthcare system makeover and better patient care
Julie Marechal-Jamil, Biosimilars Policy & Science, Medicines for Europe
Nov 1012:30
Conference pass

New clinical data for Asthma trials

Non-Oncology Immunotherapy
  • IL-33 is a pro-inflammatory cytokine implicated in the pathogenesis of many diseases including asthma  
  • Blocking IL-33 is protective in animal models of airway inflammation 
  • Tested anti-IL33 receptor blocking antibody in human asthma 
Rajita Pappu, Senior Scientist, Genentech
Nov 1012:30
Conference pass

The development of Vdelta1 Gamma Delta T cell platforms for use in next generation allogeneic CAR therapies

Cell & Gene Therapy
  • Characterization of gamma delta T cells as allogeneic pipeline products
  • Novel methods to enable manufacturing of blood and tissue resident gamma delta T cell products
  • Unique gene engineering tailored to gamma delta T cells to enable next generation CAR technologies
Nov 1012:40
Conference pass

ADCITMER®, an ADC for neuroendocrine carcinoma

Armed Antibodies
  • McSAF Inside®, disulfide rebridging technology for ADCs
  • ADCITMER® product targeting CD56 (NCAM)
  • Proof of concept in a Merkel Cell Carcinoma model
Nov 1012:40
Conference pass

Antibodies with on/off switches: Engineering strategies for fine-tuning of antibody activity

Bispecifics & Multispecifics
  • Target binding and effector functions of antibodies can be conditionally blocked
  • Protein engineering enables installation of antibody blocking and activation modules
  • Examples for generation of conditionally active antibodies and application options are provided
Anti-tumor antibodies often suffer from a narrow therapeutic window due to expression of the antibody target on non-tumor tissue or insufficiently controlled effector functions. We developed several routes for modulating antibody activity in the tumor microenvironment that rely on pH and/or tumor protease-dependent antibody activation. This is achieved by implementing pH-dependent target binding, thereby generating high affinity binding in the acidic tumor microenvironment. Alternatively, efficient conditional paratope blockade can be installed by tailor-made anti-idiotype shark-derived vNAR modules. In addition, a novel antibody format is presented, where a Fc masking unit conditionally blocks effector function, which is regained in the TME. These generic strategies pave the way to fine-tune antibody activities aimed at widening the therapeutic window.
Harald Kolmar, Head of department applied biochemistry, TU Darmstadt Biochemie
Nov 1012:40
Conference pass

Development of new protease-sensitive masked antibodies

Protein Engineering
  • Masked antibodies are only activated in the tumor by specific proteases
  • Such antibodies have decreased off-site effects
  • An efficient way to generate masked antibodies is here reported
Benjamí Oller-Salvia, Assistant Professor, Ramon Llull University (URL)
Nov 1012:40
Conference pass

Using mass spectrometry for release testing in a quality control laboratory: points to consider for user-friendly data evaluation

CMC & Developability
  • Quality control identity testing using mass spectrometry
  • Automated and user-friendly data evaluation
  • Multi-attribute monitoring with low-resolution mass spectrometry
Patrick Bulau, Senior Principal Scientist, Roche Pharma
Nov 1014:20
Conference pass

Bispecific anti-PD1/IL7 preclinical evaluation

Antibodies for Immunotherapy
  • Optimized format for improve PK/PD profile
  • Preclinical efficacy in syngeneic orthotopic tumor models and humanized mice
  • Selective activation of PD1+ CD127+ progenitor T cells
Nicolas Poirier, CSO, O.S.E. Immunotherapeutics
Nov 1014:20
Conference pass

Creating a sustainable future for Biosimilars

Biosimilars Sustainability
Isabell Remus, Head Biosimilars & Specialty Business, Europe, Sandoz
matthew turner, Head government affairs Europe, ROW, Fresenius Kabi
Nov 1014:20
Conference pass

Linker matters: highly stable and efficient ADCs made with native antibodies and peptide linkers

Armed Antibodies
  • ADCs are generated from native antibodies ‘off-the-shelf’ in one step using various payloads
  • Resulting ADCs are very well defined and show favorable biophysical properties
  • Araris ADC shows improved efficacy vs. FDA-approved ADC in head-to-head studyin mice
Philipp Spycher, Psi Founder Fellow, Paul Scherrer Institut
Nov 1014:20
Conference pass

Oral DNA Cancer Vaccination in Combination with Checkpoint Inhibitors

Combination Therapies
  • VEGFR-2 targeting T-cells and antiPD-L1 checkpoint inhibition
  • Personalized neoantigen treatment combined with CPIs
  • Rationale of early combination treatment
Nov 1014:20
Conference pass

Structural lessons from antibodies developed against disordered peptide antigens as tools for the clinical application of PASylation technology

mAbs
  • PASylation is a biological alternative to PEGylation to generate biopharmaceuticals with extended plasma half-life
  • Structurally disordered (poly)peptides such as PAS sequences composed of Pro, Ala and/or Ser represent "difficult antigens"
  • High affinity anti-PA(S) MAbs reveal peculiar ways to achieve molecular recognition of such feature-less PAS sequences
Arne Skerra, Professor - Biological Chemistry, TU Munich
Nov 1014:20
Conference pass

Title TBA

CMC & Developability
Patrick Merkle, Researcher, Novartis
Nov 1014:20
Conference pass
Nov 1014:20
Conference pass

Title TBA

Biosimilars in Oncology
Antonella Cardone, Director, European Cancer Patient Coalition
Nov 1014:40
Conference pass

APC-targeted vaccines as a platform technology

Neoantigens & Therapeutic Vaccines
Nov 1014:40
Conference pass

Title TBA

mAbs
Senior Representative, Genovac
Nov 1014:40
Conference pass

Title TBA

Armed Antibodies
Samuele Cazzamalli, Group Head, Philochem
Nov 1015:00
Conference pass

A Symphony of Separation Techniques Hyphenated to MS for In-Depth Characterization - Applications and Case Studies from a Biopharmaceutical Development Lab

CMC & Developability
  • The strength of combining orthogonal separation techniques with mass spectrometry for biopharmaceutical characterization will be discussed
  • The importance of high quality characterization data in supporting process and formulation development will be highlighted
  • Multiple case studies from pre-clinical and clinical development will be presented
Dan Bach Kristensen, Principal Scientist, Symphogen
Nov 1015:00
Conference pass

Combination therapy to fight cancer

Combination Therapies
  • Combining different modalities of epigenetic therapy
  • Combining epigenetic therapy with chemotherapy to reverse chemo resistance
  • Combining epigenetic therapy with immunotherapy
Nov 1015:00
Conference pass

Impact of human and non-human N-linked glycans on in vivo clearance of monoclonal antibody

mAbs
  • We hypothesized than immunogenic glycan structures can have immune-mediated clearance, resulting in faster clearance from in vivo circulation than non-immunogenic structures.
  • We developed a procedure to purify and analyze N-linked glycan profile of a therapeutic IgG1 from clinical serum samples.
  • The relative clearance of antibody containing human and non-human glycans are compared and discussed to assess the immunogenicity risk of non-human glycans.
Methal Albarghouthi, Director, Analytical Sciences, AstraZeneca
Nov 1015:00
Conference pass

Title TBA

Biosimilars in Oncology
Eva Rahman Kabir, Professor, Brac University
Nov 1015:00
Conference pass

Title TBA

Biosimilars Sustainability
Sundar Ramanan, Vice President, Head, Global Regulatory Affairs, Biocon Pharmaceuticals
Nov 1015:00
Conference pass

TRuC T cells: Leveraging the potential of the entire TCR in solid tumors

Cell & Gene Therapy
  • Will describe the TRuC T cell platform
  • Will describe the advantages of TRuC T cells over CAR T cells in solid tumors
  • Will provide details around the ongoing clinical trials with TRuC T cells
Nov 1015:20
Conference pass

Development of Antibody Fragment Drug Conjugates (FDCs), tailored for Solid Tumours

Armed Antibodies
  • Antikor’s FDC platform based on human single-chain Fvs, optimised for high-DAR bioconjugation
  • Preclinical data on ANT-043 (HER2-targeted FDC) and ANT-045 (target to be disclosed)
  • Development plan for ANT-045 and designing future FDC products.
Mahendra Deonarain, CEO, Antikor
Nov 1015:20
Conference pass

New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Neoantigens & Therapeutic Vaccines
  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneiccell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • The technology can be applied for any cancer
Eric Halioua, President & CEO, PDC*line pharma SA
Nov 1015:20
Conference pass

Panel discussion: Challenges around combination therapies

Combination Therapies
Christophe Le Tourneau, Head Of Clinical Research, Department Of Medical Oncology, Curie Institute
Nov 1015:20
Conference pass

Title TBA

CMC & Developability
Sara Carillo, Applications Development Team Leader, NIBRT
Nov 1015:20
Conference pass

Title TBA

Antibodies for Immunotherapy
Peter Lowe, Director, Biologics Generation And Optimization, Pierre Fabre
Nov 1015:20
Conference pass

Title TBA

mAbs
Genscript
Nov 1015:20
Conference pass

Title TBA

Biosimilars in Oncology
  • How successful has adoption of biosimilarsin cancer been in the UK
  • What should now guide our decision making about choice of biosimilar
  • Is the future a switch every couple of years?
Robert Duncombe, Medical Director, The Christie N.H.S. Foundation Trust
Nov 1015:40
Conference pass

Avoiding ADC Misdirection: Designing clinically effective agents from in vitro, in vivo, and in silico data

Armed Antibodies
  • The development of antibody drug conjugates (ADCs) is fundamentally different than both small molecule and macromolecular drug development and translation
  • Results from in vitro and preclinical animal studies often do not scale to the clinic due to delivery challenges and intrinsic sensitivity/tolerability differences
  • A combination of in silico and in vivo experiments can be designed to better represent the clinical scenario, using successful ADCs as an example, to aid in pipeline selection
Greg Thurber, Assistant Professor Of Chemical Engineering, University of Michigan
Nov 1015:40
Conference pass

Development challenges of monoclonal antibody formulations

mAbs
  • Formulation and manufacturing process
  • High concentration monoclonal antibody formulations
  • Analytical characterisation of monoclonal antibody drug products
Eva Kollar, Team Lead, Formulation Development, Biotechnology, Gedeon Richter PLC
Nov 1015:40
Conference pass

Harnessing innate immunity in cancer therapy

Antibodies for Immunotherapy
  • New therapies that promote antitumor immunity have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies
  • Only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy
  • Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumor control. We will present innovative anti-tumor therapies based on the manipulation of the innate immune system
Nov 1015:40
Conference pass

Homocitrullination of lysine residues mediated by MDSCs in the tumour environment makes an excellent target for cancer Immunotherapy

Neoantigens & Therapeutic Vaccines
  • Homocitrullinationis the post-translational modification (PTM) of lysine by cyanate derived from MPO expressed by MDSC
  • We have shownhomocitrullinationcreates neo-epitopes that are excellent targets for T cell mediated anti-tumour immunity
  • In addition we show that a repertoire of T cells exists in humans capable of responding tohomocitrullinatedvimentin and aldolase peptides that would support the targeting ofhomocitrullinatedproteins for cancer therapy
Nov 1015:40
Conference pass

Multi-Attribute Monitoring (MAM)” for process development of Nanobody and Synthorin drug candidates

CMC & Developability
  • An end-to-end automated LC-MS methodology to assess CQAs in Nanobodies and Synthorins is presented
  • Different examples for the analyses of multiple CQAs of both new Biologic modalities during process development are demonstrated
  • The presentation will provide insights into MAM method development from identification of pCQAs to the fully established automated LC-MS approach including software driven data analysis
Udo Roth, Laboratory Head MS, Sanofi Pasteur
Nov 1015:40
Conference pass

Title TBA

Biosimilars in Oncology
Johan De Munter, Executive Board Member, European Oncology Nursing Society
Nov 1015:40
Conference pass

Title TBA

Biosimilars Sustainability
mr Florian Bieber, Vice President Of Clinical Development And Drug Safety, Sandoz
Nov 1016:30
Conference pass

Innovative Biosimilars Adoption Strategies and post COVID-19 Healthcare Recovery

Biosimilars Real World Evidence and Pharmacovigilance
  • COVID-19 has caused a serious global public health and economic crisis.
  • Large molecule biologic medications are the driving force behind high drug costs.  Innovative formulary management can help reduce drug costs without compromising patient care.
  • Biosimilar products are highlysimilar tobrand name biologics and are a fraction of the cost.  100 billion dollars can potentially be saved via the utilization of biosimilars.  Thus, biosimilars can help alleviate financial burdens during this challenging time.
Sophia Humphreys, Director of System Pharmacy, Providence Health System
Nov 1016:30
Conference pass

Title TBA

Biosimilars in Oncology
Mohamed Khater, Samsung Bioepis
Nov 1016:40
Conference pass

ADC Advances

Armed Antibodies
  • Stable bioconjugation to native antibodies with precise control of DAR
  • New mechanisms of rapid linker cleavage upon ADC internalisation
  • New cytotoxins for ADCs
David Spring, Professor, University of Cambridge
Nov 1016:40
Conference pass

Antibody-cytokine fusions for cancer therapy with “activity-on-demand”

Targeting the Tumour Microenvironment
  • Certain antibody-cytokine fusions are able to selectively localize on solid tumors and promote a potent anti-cancer activity
  • Products which gain activity upon antigen binding are particularly attractive
  • I will present a thorough in vitro and in vivo characterization of products with potent anti-cancer activity
Nov 1016:40
Conference pass

Improving cancer immunotherapy in a sweet way: How glycans can be used as targets for CAR T cell therapy

Cell & Gene Therapy
  • Cancer-associated changes of glycosylation
  • Enzymatic modulation of cancer-associated glycosylation
  • Glycan targets for CAR T cell therapy
Nov 1016:40
Conference pass

Lightning Fast Bispecifics - Rapid generation of modular bispecific antibodies with pyridazinediones

Research Hub
  • We have developed pyridazinediones (PDs) to rapidly generate bsAbs from Fabs of commercially available mAbs
  • Method relies on fast BCN-tetrazine click chemistry and allows subsequent dual modification of bsAb (e.g. to generate bsADC)
  • Applications of technology are currently being explored in collaborations
Peter Szijj, Phd Student, University College London
Nov 1016:40
Conference pass

Title TBA

Antibodies for Immunotherapy
Johannes Vom Berg, Groupleader, University of Zurich
Nov 1016:40
Conference pass

Title TBA

mAbs
Rene Assenberg, Associate Director, Janssen Pharmaceutical
Nov 1016:40
Conference pass

Title TBA

Proteomics & Mass Spectrometry
Soraya Hölper, Lab Head Mass Spectrometry, Sanofi - Biologics Research
Nov 1017:00
Conference pass

Baculovirus-free Insect Cell Expression System for expression of antibodies, antigens and VLPs

Research Hub
  • Valuable alternative expression system to mammalian expression
  • Especially suited for difficult to express antigens like the spike protein
  • VLP expression
Maren Schubert, Postdoc, Technical University of Braunschweig
Nov 1017:00
Conference pass

Title TBA

Antibodies for Immunotherapy
Marjolein Van Egmond, Professor Of Oncology And Inflammation, VU University Medical Center Amsterdam
Nov 1017:00
Conference pass

Title TBA

mAbs
Reserved for Sino Biological
Nov 1017:10
Conference pass

Biosimilars: clinical data requirements-have the regulators got it right?

Biosimilars Real World Evidence and Pharmacovigilance
  • Why do biosimilars differ from generic drugs?
  • Drawing on totality.
  • What residual uncertainties need to be addressed by clinical data?
  • Challenges and value of therapeutic equivalence trials.
Cecil Nick, Vice President - Technical, Parexel
Nov 1017:20
Conference pass

Adoptive T Cell Therapy in Immuno-Oncology

Cell & Gene Therapy
  • CAR-T cells
  • TCR-T cells
  • Tumor Infiltrating Lymphocytes (TILs)
Nov 1017:20
Conference pass

Glycoform-resolved pharmacokinetic studies by combining glycoengineering and bottom-up glycoprotein analysis

Proteomics & Mass Spectrometry
  • Glycoengineering and analytical approaches will be explained.
  • The strength of the approach will be demonstrated by clarifying the differential impact of exposed core- and outer-arm mannose to antibody PK.
  • Applications to different animal models, administration routes and therapeutic proteins will be discussed.
David Falck, Assistant Professor, Leiden University Medical Center (Netherlands)
Nov 1017:20
Conference pass

Targeting proteins with biologicals inside cells

Research Hub
  • Targeting proteins as an alternative to classic strategies
  • Aapproaches and applications of utilizing antibodies inside cells
  • Chemicals for delivering macromolecules into cells
Andrea Marschall, Postdoctoral, Brandeis University
Nov 1017:20
Conference pass

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): An ADC Perspective.

Armed Antibodies
  • Developed for ovarian and endometrial cancer treatment
  • Preclinical in vivo and 3D ex vivo characterisation
  • Discovery pipeline.
Nov 1017:20
Conference pass

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): An ADC Perspective.

Armed Antibodies
  • Developed for ovarian and endometrial cancer treatment
  • Preclinical in vivo and 3D ex vivo characterisation
  • Discovery pipeline.
Nov 1017:20
Conference pass

The Biologic Revolution in Inflammatory Bowel Disease: Hits, Misses and What Comes Next

mAbs
  • Progress made in IBD medicine during the biologic era
  • Ongoing unmet needs despite the advent of biologics
  • Future directions for biologics in IBD
Mark Samaan, Consultant Gastroenterologist, Guy’s and St Thomas N.H.S Foundation Trust
Nov 1017:20
Conference pass

Title TBA

Antibodies for Immunotherapy
Harbani Malik, Senior Scientist, Teneobio
Nov 1017:20
Conference pass

Tripokin: tumor targeted delivery of IL2 potentiated by TN

Targeting the Tumour Microenvironment
  • Tripokinis an antibody fusion protein featuring both IL2 and TNF in one product
  • IL2 and TNF have a synergistic mechanism of action
  • Tripokinshows a strong anti-cancer activity in mouse models of cancer both as single agent andin combination with immune check-point inhibitors
Nov 1017:30
Conference pass

The importance of Biosimilars in Oncology

Biosimilars in Oncology
Andrew Spiegel, Executive Director, Globol Colon Cancer Association
Antonella Cardone, Director, European Cancer Patient Coalition
Mohamed Khater, Samsung Bioepis
Nov 1017:30
Conference pass

Title TBA

Biosimilars Real World Evidence and Pharmacovigilance
Kalveer Flora, Lead Rheumatology And Biosimilars Specialist Pharmacist, London North West University Healthcare NHS Trust
Nov 1017:40
Conference pass

Bispecific γδ-T cell engagers for cancer immunotherapy

Antibodies for Immunotherapy
  • Vγ9Vδ2-T cells constitute the largest γδ-T cell subset in human peripheral blood and are powerful anti-tumor immune effector cells.
  • Bispecific antibodies designed to engage Vγ9Vδ2-T cells and their use for cancer immunotherapy will be discussed
Hans Van Der Vliet, Chief Scientific Officer And Senior Vice President, Lava Therapeutics
Nov 1017:40
Conference pass

High Throughput and Format-agnostic Mispairing Assay for Multispecific Antibodies using Intact Mass Spectrometry

Proteomics & Mass Spectrometry
We developed a high throughput mispairing assay using intact mass spectrometry. This assay can support screening campaigns and detect mispaired species of ~1000 molecules in three weeks by one person. As proof of concept the assay was used to detect and perform relative quantification of mispaired species in trispecific antibodies.”
Jennifer Jung, Lab Head Mass Spectrometry, sanofi
Nov 1017:40
Conference pass

IgA tot target MDSC in the TME

Targeting the Tumour Microenvironment
  • IgA is very potent in activating neutrophils to kill cancer cells
  • Can suppressive myeloid cells (MDSC) still killtumorcells?
  • Can IgA revert or prevent the suppressive phenotype of M+DSC?
Nov 1017:40
Conference pass

Next generation antibody drug conjugates and nanomedicine

Armed Antibodies
  • Novel conjugation chemises
  • Novel targeting approaches
  • Payload synergies - optimised therapies
Chris Scott, Acting Director of the Patrick Johnston Centre for Cancer Research, Queen's University Belfast
Nov 1017:40
Conference pass

Optimal use of mAbs (biotherapeutics); from pregnancy, via babies to long-term treatment

mAbs
Annick De Vries, Head Diagnostics, Biologics, Sanquin
Nov 1017:50
Conference pass

Title TBA

Biosimilars Real World Evidence and Pharmacovigilance
Ber Oomen, Executive Secretary And Treasurer, European Specialist Nurses Organisations

Create your personal agenda –check the favourite icon

Nov 1109:05
Conference pass

Title TBA

Antibodies Day 3 Keynotes
Andreas Plueckthun, Professor Of Biochemistry, Director, Department Of Biochemistry, University of Zurich
Nov 1109:30
Conference pass

Antibody-cytokine fusions: from discovery to Phase III clinical trials

Antibodies Day 3 Keynotes
  • Antibody-cytokine fusions for cancer therapy
  • Antibody-cytokine fusions for chronic inflammatory conditions
  • Antibody-cytokine fusions with “activity on demand”
Nov 1109:30
Conference pass

Enabling Precision Medicine In Respiratory and Immunology

Immunotherapy Day 3 Keynotes
  • New drug approvals for asthma, COPD and other common diseases remain low
  • Taking a Precision Medicine approach to find the Right Patient is part of the solution
  • By leveraging the worlds genomic data, exploiting large phenotyped cohorts and accessing target tissue non-invasively, we can change the target paradigm, linking the right target to right patient from the start
Nov 1109:55
Conference pass

Targeting FcRn for the generation of therapeutics

Antibodies Day 3 Keynotes
Sally Ward, Professor of Molecular Immunology and Director of Translational Immunology, University of Southampton
Nov 1110:40
Conference pass

The Valore Project

Biosimilars IP and Legal
Ylenia Ingrasciotta, Senior Pharmacoepidemiologist, University of Messina
Nov 1111:10
Conference pass

Exploiting the unique epitope targeting ability of soloMERs to develop new therapeutic biologics

Nanobodies, Peptides & Non-antibody Formats
  • Elasmogen has established robust, diverse platforms for the isolation of high affinity, highly selective soloMERs
  • Our lead domains demonstrate novel targeting via cryptic epitope binding across a number of target classes
  • Our lead soloMER-drug conjugate program demonstrates excellent efficacy in PDX models of TNBC
Caroline Barelle, Chief Executive Officer, Elasmogen
Nov 1111:10
Conference pass

Patenting Antibodies at the EPO – an update of the Examination Guidelines

Investment & Patents
The practice followed at the EPO to examine applications related to monoclonal antibodies has been incorporated into the new Examination Guidelines which were published in March 2021. The presentation will summarize the most relevant aspects incorporated into the guidelines and will also draw attention to other aspects that are becoming increasingly relevant are likely to be introduced into the guidelines in the near future.
Helena Domingues, Patent Examiner, European Patent Office
Nov 1111:10
Conference pass

Targeting bi-specific biologics to autoimmune disease tissues

Antibodies for Immunotherapy
  • Bi-specific biologics such as immunocytokines and DVD-Ig permit the disease tissue specific targeting of active payloads
  • These formats maybe engineered as prodrugs with proteolytic linkers that minimize systemic payload activity without compromising activity
Andrew Goodearl, Director, Abbvie
Nov 1111:10
Conference pass

Title TBA

Analytics, Screening & Immune Repertoire Technologies
Christoph Merten, Professor, Laboratory for Biomedical Microfluidics, EPFL
Nov 1111:10
Conference pass

Title TBA

Computational Approaches
Pietro Sormanni, Group Leader, University of Cambridge
Nov 1111:10
Conference pass

Title TBA

Biosimilars Pricing and Payment Models
Ross Day, Former Director, Pharmacy Contracting, Vizient Inc
Nov 1111:10
Conference pass
Nov 1111:10
Conference pass

Understanding mechanism of action in humans- the importance of translational studies in early phase IO clinical trials

Precision Immunotherapy & Biomarkers
  • There is a growing appreciation of the limitations of preclinical cancer models in defining mechanisms and predicting response
  • Humans are the only truly applicable animal model
  • Maximising translational data from early clinical trials is key to unlocking mechanisms and rationalising combination therapy
Philip Beer, Physician Scientist And Precision Oncology Specialist, Sanger Institute
Nov 1111:30
Conference pass

Combining magnetic resonance imaging with systemic monocyte phenotype for GBM management

Precision Immunotherapy & Biomarkers
  • Magnetic resonance imaging (MRI) is the gold standard for glioblastoma (GBM) patient evaluation. Additional non-invasive diagnostic modalities are needed
  • GBM is heavily infiltrated withtumorassociated macrophages that can be found in peripheral blood
  • FKBP51s supports alternative macrophage polarization
  • After surgery, MRI diagnosis of persistingtumorcoincides with an increase of FKBP51s+ monocytes in peripheral blood
Nov 1111:30
Conference pass

Specificities on Patent Linkage and Biosimilars

Biosimilars IP and Legal
Alix Dubes, Senior Director Patent Attorney, Biosimilars at Fresenius Kabi, Fresenius Kabi
Nov 1111:30
Conference pass

Title TBA

Analytics, Screening & Immune Repertoire Technologies
Yariv Wine, Senior Lecturer And Assistant Professor, Tel Aviv University
Nov 1111:30
Conference pass

Title TBA

Computational Approaches
Senior Representative, Enpicom
Nov 1111:30
Conference pass

Title TBA

Nanobodies, Peptides & Non-antibody Formats
Markus Seeger, Associate Professor, University of Zurich
Nov 1111:50
Conference pass

Benchmarking machine-learning-based prediction and generation of antibody specificity

Computational Approaches
  • It is becoming increasingly clear that antibody-antigen binding is predictable
  • I will show experimental and synthetic data that indicate that combining sequence and structural data improves antibody specificity prediction
  • I will provide an in-silico proof-of-principle that generative machine learning can be used to generate unconstrained numbers of epitope-specific antibody binders
Victor Greiff, Associate Professor, Department Of Immunology, The University of Oslo
Nov 1111:50
Conference pass

Bispecific DART Molecules: From Bench to the Bedside

Antibodies for Immunotherapy
  • Bispecific DART molecules for redirected T-cell killing
  • Combinatorial checkpoint inhibition via bispecific DART molecules
  • Current status and future opportunities
Ezio Bonvini, Chief Scientific Officer, MacroGenics
Nov 1112:10
Conference pass

Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors

Precision Immunotherapy & Biomarkers
  • Circulating tumor DNA (ctDNA) is shed into the bloodstream and serves as potential predictive or prognostic biomarker
  • Changes in mutantctDNAlevels in plasmacfDNAdetected withddPCRorctNGSare associated with overall survival in NSCLC patients treated with immune checkpoint inhibitors
  • Interpretation ofctDNANGS results needs to account for clonal hematopoiesis of indeterminate potential (CHIP) representing variants incfDNAunrelated to the lung cancer
Nov 1112:10
Conference pass

How to bypass legal challenges and bring a biosimilar to market

Biosimilars IP and Legal
Alix Dubes, Senior Director Patent Attorney, Biosimilars at Fresenius Kabi, Fresenius Kabi
David Lancaster, Partner, Pinsent Masons LLP
Nov 1112:10
Conference pass

Humanization of antibodies using a machine learning approach on large-scale repertoire data

Analytics, Screening & Immune Repertoire Technologies
  • Monoclonal antibody therapeutics are often produced from non-human sources and can therefore generate immunogenic responses in humans.
  • I will describe our novel, computational humanization tool, Hu-mAb, that suggests mutations to an input sequence to reduce its immunogenicity.
  • Hu-mAb is an effective replacement for trial-and-error humanization experiments, producing similar results in a fraction of the time.
Nov 1112:10
Conference pass

New tricks for old targets: Fc-enhanced CTLA-4 and TIGIT mAbs promote optimal T cell activation and improved anti-tumor immunity.

Antibodies for Immunotherapy
  • Fc-FcgR co-engagement is critical for anti-CTLA-4 and anti-TIGIT function
  • Enhanced binding to FcgRIIIA improves T cell responsiveness, independent of Treg depletion
  • Novel Fc-mechanism enhances tumor control and broadens the therapeutic potential of CTLA-4 and TIGIT therapy
Emmanuel Briend, Associate Antibody Discovery Director, Agenus
Nov 1112:10
Conference pass

Panel discussion: computational approaches for antibody discovery & development

Computational Approaches
Eliott Harfouche, Partner, Nodes Advisors
Nov 1112:10
Conference pass

Panel discussion: investing in biologics

Investment & Patents
Nanna Luneborg, Partner, Novo Ventures
Shyam Masrani, Principal, Medicxi
Nov 1112:10
Conference pass

Title TBA

Nanobodies, Peptides & Non-antibody Formats
Timothy Jenkins, H.C. Orsted Postdoctoral Fellow, Technical University of Denmark
Nov 1112:30
Conference pass

15 Years of Biosimilars - is education still needed?

Biosimilars Pricing and Payment Models
Michael Wiechmann, Global Head Medical Affairs, Sandoz
Nov 1112:30
Conference pass

Pros and cons of several trial designs for immunotherapy and the choice of endpoints

Precision Immunotherapy & Biomarkers
  • Clinical development of immune-oncology (IO) agents presents both opportunities and challenges and not all patients benefit to the same extent
  • Many factors influence trial designs and could potentially threat success of promising IO drugs:
  • Response evaluation criteria
  • Surrogate endpoints for efficacy still be in used and the need for validated  specifically for IO trials.
  • Biomarker-driven clinical studies in order to select appropriated patients.
  • Long-term toxicity monitoring and Optimizing the design of new IO agents
  • Nov 1112:30
    Conference pass

    Secretion-based live cell sorting using droplet microfluidic; application to hybridomas selection

    Analytics, Screening & Immune Repertoire Technologies
    • Single cell immunoassay
    • Single cell secretome
    • Droplet microfluidic
    • Live cell sub-population sorting
    • Secretion-based analysis of cell heterogeneity
    Alain Wagner, Research Director, Centre National De La Recherche Scientifique
    Nov 1112:30
    Conference pass

    Title TBA

    Antibodies for Immunotherapy
    David Di Lillo, Associate Director, Regeneron
    Nov 1112:30
    Conference pass

    Title TBA

    Nanobodies, Peptides & Non-antibody Formats
    Carlo Boutton, Global Head Innovation, Large Molecule Research Platform, sanofi
    Nov 1114:00
    Conference pass

    A journey of globalization — from the first biosimilar in China to global market

    Biosimilars Emerging Regions
    Ping Cao, VP, Business Development, Shanghai Henlius Biotech, Inc
    Nov 1114:20
    Conference pass

    Keynote panel discussion: Exploring clinical needs and novel indications

    Antibodies Closing Keynotes
    Moderator: Thomas Huber, Research director, Almirall
    Nov 1114:20
    Conference pass

    Pandemic changes in biosimilar use: where are we now?

    Biosimilars Patient and Physician Engagement
    Martin Perry, Consultant Physician And Rheumatologist, Honorary Senior Clinical Lecturer, NHS Greater Glasgow & Clyde
    Nov 1114:20
    Conference pass

    Title TBA

    Biosimilars Emerging Regions
    Lawrence Hill, Chief Executive Officer, Gan & Lee Pharmaceuticals USA
    Nov 1114:40
    Conference pass

    Interchangeability and Sustainability

    Biosimilars Patient and Physician Engagement
    • Differences between the US and Europe
    • Tackling barriers to entry
    Joseph McClellan, Chief Scientific Officer, Alvotech
    Nov 1115:20
    Conference pass

    Title TBA

    Biosimilars Emerging Regions
    Bert Thomas, Senior Vice President Of Business Development, Bio-Thera Solutions
    last published: 20/Jul/21 14:15 GMT